Logo image of XOMAP

XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Fundamental Analysis

NASDAQ:XOMAP - US98419J3059

26.76 USD
+0.11 (+0.41%)
Last: 9/5/2025, 8:00:02 PM
Fundamental Rating

4

XOMAP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. While XOMAP is still in line with the averages on profitability rating, there are concerns on its financial health. XOMAP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year XOMAP has reported negative net income.
In the past year XOMAP has reported a negative cash flow from operations.
In multiple years XOMAP reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: XOMAP reported negative operating cash flow in multiple years.
XOMAP Yearly Net Income VS EBIT VS OCF VS FCFXOMAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of XOMAP (-7.93%) is better than 84.66% of its industry peers.
XOMAP has a Return On Equity of -19.17%. This is amongst the best in the industry. XOMAP outperforms 85.03% of its industry peers.
XOMAP has a better Return On Invested Capital (3.73%) than 91.87% of its industry peers.
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROIC 3.73%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAP Yearly ROA, ROE, ROICXOMAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

Looking at the Operating Margin, with a value of 21.23%, XOMAP belongs to the top of the industry, outperforming 95.01% of the companies in the same industry.
XOMAP does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 21.23%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAP Yearly Profit, Operating, Gross MarginsXOMAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XOMAP is destroying value.
Compared to 1 year ago, XOMAP has more shares outstanding
The number of shares outstanding for XOMAP has been increased compared to 5 years ago.
The debt/assets ratio for XOMAP is higher compared to a year ago.
XOMAP Yearly Shares OutstandingXOMAP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAP Yearly Total Debt VS Total AssetsXOMAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.42, we must say that XOMAP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XOMAP (-5.42) is worse than 62.29% of its industry peers.
XOMAP has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.11, XOMAP is not doing good in the industry: 77.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z -5.42
ROIC/WACC0.37
WACC9.99%
XOMAP Yearly LT Debt VS Equity VS FCFXOMAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.88 indicates that XOMAP has no problem at all paying its short term obligations.
XOMAP has a Current ratio (4.88) which is in line with its industry peers.
A Quick Ratio of 4.88 indicates that XOMAP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.88, XOMAP is in line with its industry, outperforming 54.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.88
XOMAP Yearly Current Assets VS Current LiabilitesXOMAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

XOMAP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.74%.
Looking at the last year, XOMAP shows a very strong growth in Revenue. The Revenue has grown by 168.71%.
XOMAP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%

3.2 Future

Based on estimates for the next years, XOMAP will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
XOMAP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.53% yearly.
EPS Next Y117.66%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year78.53%
Revenue Next 2Y41.78%
Revenue Next 3Y35.53%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMAP Yearly Revenue VS EstimatesXOMAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMAP Yearly EPS VS EstimatesXOMAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

XOMAP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 147.66, XOMAP can be considered very expensive at the moment.
XOMAP's Price/Forward Earnings ratio is rather cheap when compared to the industry. XOMAP is cheaper than 86.88% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of XOMAP to the average of the S&P500 Index (22.66), we can say XOMAP is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 147.66
XOMAP Price Earnings VS Forward Price EarningsXOMAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

XOMAP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XOMAP is cheaper than 91.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 31.46
XOMAP Per share dataXOMAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

XOMAP's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XOMAP's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.5%
EPS Next 3Y37.32%

More info and screens

5

5. Dividend

5.1 Amount

XOMAP has a Yearly Dividend Yield of 8.06%, which is a nice return.
Compared to an average industry Dividend Yield of 167.86, XOMAP pays a better dividend. On top of this XOMAP pays more dividend than 99.45% of the companies listed in the same industry.
XOMAP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.45.
Industry RankSector Rank
Dividend Yield 8.06%

5.2 History

XOMAP has been paying a dividend for over 5 years, so it has already some track record.
XOMAP has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAP Yearly Dividends per shareXOMAP Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

XOMAP has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-30.88%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
XOMAP Yearly Income VS Free CF VS DividendXOMAP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

More info and screens

XOMA ROYALTY CORP - XOMA 8 5/8 PERP

NASDAQ:XOMAP (9/5/2025, 8:00:02 PM)

26.76

+0.11 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners62.65%
Inst Owner ChangeN/A
Ins Owners1.34%
Ins Owner ChangeN/A
Market Cap323.53M
Analysts82
Price Target52.65 (96.75%)
Short Float %0%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield 8.06%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years3
Ex-Date07-03 2025-07-03 (0.53906)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)-15.86%
PT rev (3m)-23.41%
EPS NQ rev (1m)72.73%
EPS NQ rev (3m)74.52%
EPS NY rev (1m)278.33%
EPS NY rev (3m)165.66%
Revenue NQ rev (1m)8.53%
Revenue NQ rev (3m)22%
Revenue NY rev (1m)6.66%
Revenue NY rev (3m)6.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 147.66
P/S 7.2
P/FCF N/A
P/OCF N/A
P/B 3.5
P/tB 6.88
EV/EBITDA 31.46
EPS(TTM)-1.54
EYN/A
EPS(NY)0.18
Fwd EY0.68%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROCE 4.73%
ROIC 3.73%
ROICexc 6.38%
ROICexgc 10.37%
OM 21.23%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 9.33
Cap/Depr 1425.07%
Cap/Sales 44.89%
Interest Coverage 0.78
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.88
Altman-Z -5.42
F-Score5
WACC9.99%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y117.66%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year78.53%
Revenue Next 2Y41.78%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A